MyMD Pharmaceuticals Enrolls First Individual in Stage 2 Clinical Trial of MYMD-1 as a Treatment for Delaying Aging and Expanding Healthy And Balanced Life Expectancy

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc – Stock Price, Quote and News (” MyMD” or “the Firm”), a clinical phase pharmaceutical firm committed to expanding healthy life-span, today announced that the very first individual has been signed up in the Company’s Phase 2 clinical test of lead prospect MYMD-1, a dental immune regulator medicine, as a treatment for delaying aging and also expanding healthy and balanced life expectancy.

The primary endpoint for the Phase 2 double-blind, placebo-controlled professional test is to achieve a reduction in the distributing levels of (TNF-α), growth necrosis element receptor I (TNFRI) and IL-6. TNF-α and also IL-6 are the proteins in the body that create swelling and assist turn on the procedure of aging. The second actions of the test will certainly be the security, tolerability, and also pharmacokinetics in this population of people.

” In a Stage 1 medical trial of MYMD-1, we showed the drug’s statistically substantial efficacy in decreasing levels of TNF-α, a principal in causing pathological aging, in the blood. The FDA has authorized TNF-α decrease as the key endpoint for our Stage 2 study, which we believe positions us well for an effective Stage 2 result,” stated Chris Chapman, M.D., President, Supervisor as well as Chief Medical Police Officer of MyMD. “The initiation of individual enrollment in this research study advances our goal to reduce the aging process, stop loss of muscle cells in aging, limitation frailty, as well as prolong healthy life expectancy.”

MyMD has actually stated that there are no FDA-approved drugs for dealing with aging problems and prolonging healthy life expectancy people, a market expected to be at least $600 billion by 20251 according to a major financial investment financial institution. TNF-α blockers are the most prescribed medications by revenue, a global market of around $40 billion per year,2 and also, according to Nature Aging journal,3 a slowdown in maturing that would increase life expectancy by one year deserves $38 trillion as well as by ten years is worth $367 trillion.

In addition to aging, MYMD-1’s unique action in regulating the body immune system as well as treating chronic swelling is being created for the therapy of autoimmune disease, consisting of rheumatoid arthritis (RA), numerous sclerosis (MS), diabetic issues, and inflammatory bowel condition.

” We intend to begin creating protocols for a Stage 2 pilot research of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The increasing prevalence of rheumatoid joint inflammation and various other autoimmune and inflammatory illness are driving need for TNF inhibitors like MYMD-1, as well as our team believe our orally provided drug with very reduced toxicity would be turbulent to the $60 billion market for RA if authorized by the FDA for this sign.”

Rheumatoid joint inflammation affects about 40 million individuals around the world.4.

Regarding MYMD-1.

Initially created for autoimmune illness, MYMD-1’s primary function is to slow down the aging process, avoid sarcopenia and also frailty, as well as prolong healthy life expectancy. Since it can go across the blood-brain obstacle as well as access to the central nerve system (CNS), MYMD-1 is likewise positioned to be a feasible treatment for brain-related conditions. Its device of activity as well as effectiveness in diseases consisting of several sclerosis (MS) as well as thyroiditis have been examined via cooperations with several academic organizations. MYMD-1 is also revealing promise in pre-clinical studies as a possible therapy for message- COVID-19 problems and also as an anti-fibrotic as well as anti-proliferation therapeutic.

MYMD-1 has actually revealed performance in pre-clinical researches in regulating the immune system by doing as a discerning inhibitor of tumor necrosis factor-alpha (TNF-α), a chauffeur of persistent inflammation. Unlike other therapies, MYMD-1 has been displayed in these pre-clinical studies to precisely obstruct TNF-α when it comes to be overactivated in autoimmune diseases as well as cytokine tornados, yet not block it from doing its typical job of being an initial -responder to any kind of regular type of modest infection. MYMD-1’s ease of oral dosing is an additional differentiator contrasted to presently offered TNF-α blockers, all of which require distribution by shot or infusion. No accepted TNF prevention has ever before been dosed orally. On top of that, the drug is not immunosuppressive as well as has actually not been shown to create the major adverse effects typical with typical treatments that deal with swelling.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical firm dedicated to extending healthy and balanced life expectancy, is focused on establishing two unique restorative systems that treat the sources of disease as opposed to just dealing with the symptoms. MYMD-1 is a medication platform based upon a medical phase small particle that controls the body immune system to regulate TNF-α, which drives chronic swelling, and also other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to postpone aging, rise durability, and also deal with autoimmune illness and COVID-19- connected anxiety. The Business’s 2nd medicine platform, Supera-CBD, is being created to deal with persistent discomfort, dependency and also epilepsy. Supera-CBD is an unique artificial by-product of cannabidiol (CBD) and also is being created to address and surpass the quickly growing CBD market, that includes both FDA approved medications and also CBD products not currently regulated as drugs. To learn more, go to www.mymd.com.